Interview with Dr. Sungwon Lim CEO and Co-Founder of ImpriMed

Share:

Innovating with Scott Amyx

Business


ImpriMed uses artificial intelligence on live cancer cell analytics to predict how a patient will respond to cancer therapy drugs before taking them.